TY - JOUR
KW - Addiction
KW - Analgesics, Opioid/adverse effects/therapeutic use
KW - Behavior, Addictive
KW - buprenorphine
KW - Buprenorphine/adverse effects/therapeutic use
KW - Craving/drug effects
KW - drug treatment
KW - Humans
KW - Medical Toxicology
KW - Opiate Substitution Treatment/adverse effects/methods
KW - opioid dependence
KW - Opioid-Related Disorders/diagnosis/drug therapy/psychology
KW - Quality of Life
KW - Risk Factors
KW - Substance Abuse Treatment Centers
KW - Toxicology/methods
KW - Treatment Outcome
AU - T. J. Wiegand
A1 - 
AB - Buprenorphine represents a safe and effective therapy for treating opioid dependence, alleviating craving and withdrawal symptoms in opioid-dependent patients. Buprenorphine has a "blocking" effect against the action of other opioids at the mu-receptor, preventing not only opioid-induced euphoria, but CNS and respiratory depressant effects as well. Buprenorphine was approved for the treatment of opioid dependence in 2002 after the passage of Drug Abuse Treatment Act 2000 (DATA 2000) which allowed clinicians to treat opioid-dependent patients with specifically named opioid agonist therapies in an office setting. Buprenorphine programs reduce the prevalence of HIV and hepatitis C and reduce criminal behaviors associated with illicit drug use. Patients stabilized on buprenorphine have increased employment, enhanced engagement with social services, and better overall health and well-being.
BT - Journal of medical toxicology : official journal of the American College of Medical Toxicology
C5 - Opioids & Substance Use
CP - 1
CY - United States
DO - 10.1007/s13181-015-0518-4
IS - 1
JF - Journal of medical toxicology : official journal of the American College of Medical Toxicology
N2 - Buprenorphine represents a safe and effective therapy for treating opioid dependence, alleviating craving and withdrawal symptoms in opioid-dependent patients. Buprenorphine has a "blocking" effect against the action of other opioids at the mu-receptor, preventing not only opioid-induced euphoria, but CNS and respiratory depressant effects as well. Buprenorphine was approved for the treatment of opioid dependence in 2002 after the passage of Drug Abuse Treatment Act 2000 (DATA 2000) which allowed clinicians to treat opioid-dependent patients with specifically named opioid agonist therapies in an office setting. Buprenorphine programs reduce the prevalence of HIV and hepatitis C and reduce criminal behaviors associated with illicit drug use. Patients stabilized on buprenorphine have increased employment, enhanced engagement with social services, and better overall health and well-being.
PP - United States
PY - 2016
SN - 1937-6995; 1556-9039
SP - 64
EP - 70
EP - 
T1 - The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice
T2 - Journal of medical toxicology : official journal of the American College of Medical Toxicology
TI - The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice
U1 - Opioids & Substance Use
U2 - 26574020
U3 - 10.1007/s13181-015-0518-4
VL - 12
VO - 1937-6995; 1556-9039
Y1 - 2016
ER -